BNOX

Bionomics Ltd

Add to Watchlist

Advanced Chart

3.037

0.000(0.000%)

Overview
Forecast
Valuation

High

3.0372

Open

3.0372

VWAP

3.04

Vol

Mkt Cap

9.82M

Low

3.0372

Amount

EV/EBITDA(TTM)

Total Shares

13.25M

-7.63M

EV/OCF(TTM)

P/S(TTM)

Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.

0 Analyst Rating

Wall Street analysts forecast BNOX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNOX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 3.037

Low

Averages

High

Current: 3.037

Low

Averages

High

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-08-01

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-08-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-07-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-07-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-06-12

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-06-12

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bionomics Ltd (BNOX.O) is -0.62, compared to its 5-year average forward P/E of -124.35. For a more detailed relative valuation and DCF analysis to assess Bionomics Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-124.35

Current PE

-0.62

Overvalued PE

116.29

Undervalued PE

-364.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.66

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.75

Undervalued EV/EBITDA

-2.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.60

Current PS

0.00

Overvalued PS

19.70

Undervalued PS

-0.49